Aerie announces phase 3 registration trial of Rhopressa in Canada

Aerie Pharmaceuticals announced it recently initiated a phase 3 registration trial of Rhopressa, a once-daily, triple-action eye drop designed to lower IOP in patients with glaucoma or ocular hypertension, according to a company press release. The study, Rocket 3, will evaluate safety and tolerability of Rhopressa during a 12-month period.